Endocrinology Medical News about Postmenopausal

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Transdermal Nitroglycerin Therapy May Not Prevent Early Postmenopausal Bone Loss
Journal of Clinical Endocrinology and Metabolism, 07/01/09

Wimalawansa SJ et al. - BMD changes did not substantially differ between postmenopausal women who received the dose of nitroglycerin tested, in comparison to a placebo. Once-daily dosing with 22.5 mg of transdermal-administered nitroglycerin was not effective (compliance adjusted dose was -16 mg/day).

Exclusive Author Commentary
Sunil J. Wimalawansam, MD, PhD, MBA, 08/02/09

This single center, three-year double-blind, randomized, clinical study in 188 early postmenopausal subjects, half received 22.5 mg of transdermal nitroglycerin (average dose ~16 mg/day) plus calcium plus vitamin D, while the control group received a placebo ointment, calcium and vitamin D. The primary endpoint, the lumbar spine BMD did not differ significant; under dosing of subjects was the primary reason for this. Taken together with other studies, we believe that higher dosages would not only preserve BMD, but may also improve fracture rates. If this is proven the case, nitric oxide donors are likely to be the most cost-effective therapy for prevention and treatment of osteoporosis. Hence, new studies are warranted in this fires of research.

<< Previous
Bone mineral density, prevalence of vertebral fractures and bone...

Next >>
The Association between Adiponectin/Leptin Ratio and Diabetes...

Intensity and timing of physical activity in relation to postmenopausal breast cancer risk: the prospective NIH-AARP Diet and Health Study
BMC Cancer, 10/05/09 Relevance Score: 90%

Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
Therapeutics and Clinical Risk Management, 10/16/09 Relevance Score: 89%

Oestrogen plus progestin and lung cancer in postmenopausal women (Womens Health Initiative trial): a post-hoc analysis of a randomised controlled trial
The Lancet, 10/12/09 Relevance Score: 89%

Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II
Cancer Epidemiology, Biomarkers & Prevention, 10/28/09 Relevance Score: 88%

Testosterone and biological characteristics of breast cancers in postmenopausal women
Cancer Epidemiology, Biomarkers & Prevention, 10/28/09 Relevance Score: 88%